➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Harvard Business School
Colorcon
McKesson
Moodys

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,216,982


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,216,982
Title:Certain chemical entities, compositions and methods
Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
Inventor(s): Ren; Pingda (San Diego, CA), Liu; Yi (San Diego, CA), Wilson; Troy Edward (San Marino, CA), Li; Liansheng (San Diego, CA), Chan; Katrina (Fremont, CA), Rommel; Christian (La Jolla, CA)
Assignee: Intellikine LLC (La Jolla, CA)
Application Number:14/296,953
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,216,982

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) ⤷  Free Forever Trial
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) ⤷  Free Forever Trial
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) ⤷  Free Forever Trial
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,216,982

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009204483 ⤷  Free Forever Trial
Australia 2009204487 ⤷  Free Forever Trial
Australia 2010274075 ⤷  Free Forever Trial
Brazil 112012000968 ⤷  Free Forever Trial
Brazil PI0906473 ⤷  Free Forever Trial
Brazil PI0906474 ⤷  Free Forever Trial
Canada 2711446 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Harvard Business School
Moodys
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.